Stocks · News reference
Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 29, 2026, 12:46 PM
- Checked
- Jun 29, 2026, 12:50 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of
Read original at benzingaAnixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
Read original at benzinga